250 related articles for article (PubMed ID: 29574771)
1. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER.
Moradi-Kalbolandi S; Hosseinzade A; Salehi M; Merikhian P; Farahmand L
J Pharm Pharmacol; 2018 Jul; 70(7):841-854. PubMed ID: 29574771
[TBL] [Abstract][Full Text] [Related]
2. Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect.
Wang M; Hu Y; Yu T; Ma X; Wei X; Wei Y
Cancer Lett; 2018 Dec; 439():113-130. PubMed ID: 30218688
[TBL] [Abstract][Full Text] [Related]
3. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
[TBL] [Abstract][Full Text] [Related]
4. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.
Dokala A; Thakur SS
Oncogene; 2017 Apr; 36(17):2337-2344. PubMed ID: 27775071
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies targeting the epidermal growth factor receptor.
Bianco R; Daniele G; Ciardiello F; Tortora G
Curr Drug Targets; 2005 May; 6(3):275-87. PubMed ID: 15857288
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor.
Baradaran B; Majidi J; Farajnia S; Barar J; Omidi Y
Hum Antibodies; 2014; 23(1-2):13-20. PubMed ID: 25812698
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
Khelwatty SA; Essapen S; Seddon AM; Fan Z; Modjtahedi H
Br J Cancer; 2015 Sep; 113(7):1010-9. PubMed ID: 26372697
[TBL] [Abstract][Full Text] [Related]
9. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.
Kyriakopoulou K; Kefali E; Piperigkou Z; Bassiony H; Karamanos NK
Cell Signal; 2018 Nov; 51():99-109. PubMed ID: 30071291
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
11. Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.
Huang S; Peter Rodemann H; Harari PM
Recent Results Cancer Res; 2016; 198():45-87. PubMed ID: 27318681
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
Jacob W; James I; Hasmann M; Weisser M
Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EGFR pathway for cancer therapy.
Johnston JB; Navaratnam S; Pitz MW; Maniate JM; Wiechec E; Baust H; Gingerich J; Skliris GP; Murphy LC; Los M
Curr Med Chem; 2006; 13(29):3483-92. PubMed ID: 17168718
[TBL] [Abstract][Full Text] [Related]
14. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
18. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.
Herbst RS; Shin DM
Cancer; 2002 Mar; 94(5):1593-611. PubMed ID: 11920518
[TBL] [Abstract][Full Text] [Related]
20. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]